Amyloidosis: A changing clinical perspective

Hematology

Volumn 12, Issue 2, 2007, Pages 163-167

  Jacobs, Peter ^a,b,c   Ruff, Paul ^d   Wood, Lucille ^a   Moodley, Devan ^d   Mansvelt, Erna ^b  

^a Department of Haematology and Bone Marrow Transplantation Unit   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Amyloidosis; Cardiomyopathy; Multiple myeloma; Plasma cell

Indexed keywords

AMYLOID PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; PHENYLALANINE; PREDNISONE; VINCRISTINE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; BLOOD ANALYSIS; CANCER COMBINATION CHEMOTHERAPY; CELL INFILTRATION; CELL ULTRASTRUCTURE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE DURATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN PRODUCTION; IMMUNOHISTOCHEMISTRY; MALE; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; RISK ASSESSMENT; SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; BONE MARROW; BONE MARROW TRANSPLANTATION; COLCHICINE; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOPROLIFERATIVE DISORDERS; MALE; MELPHALAN; METHYLPREDNISOLONE; MIDDLE AGED; PLASMA CELLS; PREDNISONE; RADIOIMMUNOTHERAPY; SOUTH AFRICA; SURVIVAL RATE;

EID: 34247192041     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330701214350     Document Type: Article

References (39)

1. Pepys, MB (2001) Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos Transact R Soc Lond B Biol Sci, 356, pp. 203-210.
2. Gertz, MA (2002) Diagnosing primary amyloidosis. Mayo Clin Proc, 77, pp. 1278-1279.
3. Perfetti, V., Vignarelli, M Colli, Anesi, E., Garini, P., Quaglini, S., Ascari, E. and Merlini, G. (1999) The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica, 84, pp. 218-221.
4. Stavem, P., Larsen, IF and Rorvik, TO (1980) Amyloid deposits in bone marrow aspirates in primary amyloidosis. Acta Med Scand, 208, pp. 111-113.
5. Krause, JR (1977) Value of bone marrow biopsy in the diagnosis of amyloidosis. South Med J, 70, pp. 1072-1074.
6. Rajkumar, SV, Gertz, MA and Kyle, RA (1998) Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer, 82, pp. 1501-1505.
7. Zeidman, A., Sender, BZ, Yarmolovsky, A., Fradin, Z. and Mittelman, M. (2000) Severe amyloidosis with mild multiple myeloma - an unusual course. Haematologica, 30, pp. 55-59.
8. Gillmore, JD, Davies, J., Iqbal, A., Madhoo, S., Russell, NH and Hawkins, PN (2000) Allogeneic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol, 100, pp. 226-228.
9. Skinner, M., Anderson, JJ, Simms, R., Falk, R., Wang, M. and Libbey, CA (1996) Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicines only. Am J Med, 100, pp. 290-298.
10. Kingman, A. and Pereira, NL (2001) Cardiac amyloidosis. J S C Med Assoc, 97, pp. 201-206.
11. Sidoni, A., Alberti, PF, Bravi, S. and Bucciarelli, E. (1998) Amyloid tumours in the soft tissue of the legs: Case report and review of the literature. Virchows Arch, 432, pp. 563-566.
12. Nair, DR, Mehta, A., Mikhailidis, DP and Winder, AF (1997) Multiple myeloma with primary amyloidosis. J R Soc Med, 90, p. 502.
13. Kutlay, S., Hasan, T., Keven, K., Nergizoglu, G., Ates, K. and Karatan, O. (2002) Primary amyloidosis presenting with massive generalized lymphadenopathy. Leuk Lymphoma, 43, pp. 1501-1503.
14. Fonseca, R., Ahmann, GJ, Jalal, SM, Dewald, GW, Larson, DR and Therneau, TM (1998) Chromosomal abnormalities in systemic amyloidosis. Br J Haematol, 103, pp. 704-710.
15. Takeuchi, S., Iwata, M., Ogawa, M., Nagata, A., Tano, M. and Yokoi, T. (1996) Amyloidosis secondary to bronchiectasis. Nihon Kyobu Shikkan Gakkai Zasshi, 34, pp. 601-604.
16. Gatel, A., Cacoub, P. and Piette, JC (1998) AL amyloidosis combined with acquired factor V deficiency. Ann Intern Med, 128, pp. 604-605.
17. Kyle, RA, Gertz, MA, Greipp, PR, Witzig, TE, Lust, JA, Lacy, MQ and Therneau, TM (1997) A trial of three regimens for primary amyloidosis: Colchicines alone, melphalan and prednisone, and melphalan, prednisone, and colchicines. N Engl J Med, 336, pp. 1202-1207.
18. Comenzo, RL, Vosburgh, E., Falk, RH, Sanchorawala, V., Reisinger, J. and Dubrey, S. (1998) Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood, 91, pp. 3662-3670.
19. Gertz, MA, Lacy, MQ, Dispenzieri, A., Gastineau, DA, Chen, MG and Ansell, SM (2002) Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med, 113, pp. 549-555.
20. Sanchorawala, V., Wright, DG, Seldin, DC, Dember, LM, Finn, K. and Falk, RH (2001) An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant, 28, pp. 637-642.
21. Fossa, A., Muer, M., Kasper, C., Welt, A., Seeber, S. and Nowrousian, MR (1998) Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma. Leukemia, 12, pp. 422-426.
22. Gono, T., Matsuda, M., Dohi, N., Hoshi, K., Tada, T. and Sakashita, K. (2003) Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Inter Med, 42, pp. 72-77.
23. Gameren II, van, Hazenberg, BP, Jager, PL, Smith, JW and Vellenga, E. (2002) AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid, 9, pp. 165-174.
24. Sezer, O., Niemoller, K., Jakob, C., Langelotz, C., Eucker, J. and Possinger, K. (2000) Novel approaches to the treatment of primary amyloidosis. Expert Opin Investig Drugs, 9, pp. 2343-2350.
25. van Buren, M., Hené, RJ, Verdonck, LF, Verzijlbergen, FJ and Lokhorst, HM (1995) Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis. Ann Intern Med, 122, pp. 508-510.
26. Mariette, X., Clauvel, JP and Brouet, JC (1995) Intensive therapy in AL amyloidosis and light-chain deposition disease. Ann Intern Med, 123, p. 553.
27. Georgiades, CS, Neyman, EG and Fishman, EK (2002) Cross-sectional imaging of amyloidosis: An organ system-based approach. J Comput Assist Tomogr, 26, pp. 1035-1041.
28. Moreau, P., Leblond, V., Bourquelot, P., Facon, T., Huynh, A. and Caillot, D. (1998) Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients. Br J Haematol, 101, pp. 766-769.
29. Comenzo, RL, Michelle, D., LeBlanc, M., Wally, Y., Zhang, Y. and Kica, G. (1998) Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: Rationale and application. Transfusion, 38, pp. 60-69.
30. Gertz, MA, Lacy, MQ, Gastineau, DA, Inwards, DJ, Chen, MG and Tefferi, A. (2000) Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant, 26, pp. 963-969.
31. Sezer, O., Schmid, P., Schweigert, M., Heider, U., Eucker, J. and Harder, H. (1999) Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplant, 23, pp. 967-969.
32. Reich, G., Held, T., Siegert, W., Kampf, D., Dörken, B. and Maschmeyer, G. (2001) Four patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant, 27, pp. 341-343.
33. Goldman, JM, Schmitz, N., Niethammer, D. and Gratwohl, A. (1998) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe in 1998. The Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant, 21, pp. 1-7.
34. Badros, A., Barlogie, B., Siegel, E., Cottler-Fox, M., Zangari, M. and Fassas, A. (2002) Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol, 20, pp. 1295-1303.
35. Alyea, E., Weller, E., Schlossman, R., Canning, C., Webb, I. and Doss, D. (2001) T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Induction of graft-versus-myeloma effect. Blood, 98, pp. 934-939.
36. Treon, SP and Anderson, KC (2000) The use of rituximab in the treatment of malignant and non-malignant plasma cell disorders. Semin Oncol, 27, pp. 79-85.
37. Zelenetz, AD (2003) A clinical and scientific overview of tositumomab and iodine I 131 tositumomab. Semin Oncol, 30, pp. 22-30.
38. Wiseman, GA, Leigh, BR, Dunn, WL, Stabin, MG and White, CA (2003) Additional radiation absorbed dose estimates for Zevalin trade mark radioimmunotherapy. Cancer Biother Radiopharm, 18, pp. 253-258.
39. Tallman, MS (2002) Advancing the treatment of hematologic malignancies through the development of targeted interventions. Semin Hematol, 39